Red And White Vaccine Production Is Being Accelerated, The Emergency Permit Will Be Issued In June 2022

Illustration (Unsplash)

JAKARTA - Head of the Eijkman Amin Soebandrio Institute for Molecular Biology is targeting the Red and White Vaccine currently being developed to receive emergency use authorization (EUA) in June 2022.

Amin said this target was achieved after Eijkman carried out clinical trials of phases 1, 2, and 3 of the Red and White Vaccine which were held starting March 2022.

Furthermore, the clinical trial results are brought to the Food and Drug Supervisory Agency (BPOM) to issue an emergency permit for the use of the domestically produced vaccine.

"It is hoped that by mid-2022 it will be able to complete the phase 1, 2, and part 3 clinical trials so that the emergency use authorization can be obtained at the end of June 2022", Amin said at the House of Representatives (DPR RI) Commission IX working meeting, Wednesday, March 10.

Amin said that the target for obtaining EUA was ahead of the schedule proposed by PT Bio Farma. Eijkman has accelerated a number of transitions in the production process of the Red and White Vaccine.

"From the timeline proposed by Bio Farma, it is hoped that it will be completed or get EUA in November 2022. Then we make efforts to accelerate it, so it remains in June. There are savings of about 3 to 4 months," he said.

For information, the Red and White vaccine has different progress in research institutions. Vaccine trials are conducted in collaboration with research institutions, non-ministerial government agencies, and universities. Among them are LBM Eijkman, LIPI, University of Indonesia, ITB, Unair, and UGM

The development of the Red and White vaccine was carried out by the Eijkman Institute and PT Biofarma (Persero). This vaccine is expected to be completed in November 2022. The development was initiated by a research consortium under the auspices of the Ministry of Research and Technology or the National Research and Innovation Agency (BRIN).

A spokesperson for the Task Force for Handling COVID-19, Wiku Adisasmiyo said that currently the government is trying to take a step further to prepare to accelerate the procurement of vaccines to its industrial context.

The trick, the government invites private pharmaceuticals to work together in accelerating production. The goal is to guarantee the production of large amounts of vaccine.

"Currently, opportunities for cooperation with the national private industry have been opened. Either to increase production capacity, facilitate preclinical and clinical trial processes, or expand the target market", said Wiku.